ChREBP Inhibitors
ChREBP (Carbohydrate-Responsive Element-Binding Protein) inhibitors are a class of chemical compounds that function by modulating the activity of the ChREBP transcription factor, which plays a central role in glucose metabolism and lipid biosynthesis. ChREBP is activated in response to elevated glucose levels, particularly in the liver, where it translocates to the nucleus and binds to carbohydrate response elements (ChoREs) in the promoter regions of target genes. These genes are primarily involved in the synthesis of fatty acids, triglycerides, and cholesterol, as well as in the regulation of glucose metabolism. By inhibiting ChREBP, these compounds effectively reduce the expression of genes that drive the lipogenic and glycolytic pathways, leading to a decrease in the synthesis of lipids and other glucose-derived metabolites.
The molecular mechanisms through which ChREBP inhibitors exert their effects can vary, but they generally involve direct binding to the ChREBP protein, preventing its activation, nuclear translocation, or DNA binding capability. This inhibition can occur at different stages of ChREBP's activation process, such as by blocking its interaction with cofactors, disrupting its phosphorylation status, or altering its ability to sense and respond to glucose levels. As a result, ChREBP inhibitors are valuable tools for studying the regulation of glucose and lipid metabolism at a cellular and molecular level. Their use allows researchers to dissect the pathways controlled by ChREBP and to explore the broader implications of glucose-driven metabolic processes in various biological contexts.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
BAY-876 | 1799753-84-6 | sc-507539 | 5 mg | $240.00 | ||
BAY-876, a PFKFB3 inhibitor, influences glycolysis. ChREBP, linked to glycolytic metabolism, can be indirectly influenced, as PFKFB3 is involved in glycolysis. BAY-876's impact on PFKFB3 can modulate ChREBP function, potentially affecting glucose-mediated gene expression and lipogenesis. | ||||||
TOFA (5-(Tetradecyloxy)-2-furoic acid) | 54857-86-2 | sc-200653 sc-200653A | 10 mg 50 mg | $97.00 $374.00 | 15 | |
TOFA, an ACC inhibitor, affects fatty acid synthesis. ChREBP, linked to lipogenesis, can be indirectly influenced, as ACC is involved in fatty acid synthesis. TOFA's impact on ACC can modulate ChREBP function, potentially affecting lipid metabolism and ChREBP-mediated gene expression. | ||||||
GW 9662 | 22978-25-2 | sc-202641 | 5 mg | $70.00 | 30 | |
GW6471, a PPARα antagonist, influences PPARα signaling. ChREBP, regulated by PPARα, can be indirectly affected, as PPARα inhibits ChREBP activity. GW6471's impact on PPARα signaling can modulate ChREBP function, potentially influencing lipid metabolism and ChREBP-mediated gene expression. | ||||||
Wiskostatin | 253449-04-6 | sc-204399 sc-204399A sc-204399B sc-204399C | 1 mg 5 mg 25 mg 50 mg | $49.00 $124.00 $441.00 $828.00 | 4 | |
WZB117, a GLUT1 inhibitor, affects glucose transport. ChREBP, sensitive to glucose availability, can be indirectly influenced, as GLUT1 is involved in glucose transport. WZB117's impact on GLUT1 can modulate ChREBP function, potentially affecting glucose-mediated gene expression and lipogenesis. | ||||||
PF 4708671 | 1255517-76-0 | sc-361288 sc-361288A | 10 mg 50 mg | $179.00 $700.00 | 9 | |
PF-4708671, an AMPK inhibitor, modulates AMPK signaling. ChREBP, responsive to AMPK activation, can be indirectly affected, as AMPK inhibits ChREBP activity. PF-4708671's impact on AMPK signaling can modulate ChREBP function, potentially influencing glucose-responsive gene expression and lipid synthesis. | ||||||
Oleic Acid | 112-80-1 | sc-200797C sc-200797 sc-200797A sc-200797B | 1 g 10 g 100 g 250 g | $37.00 $104.00 $580.00 $1196.00 | 10 | |
2-Hydroxyoleic acid, a SCD1 inhibitor, influences lipid metabolism. ChREBP, involved in lipogenesis, can be indirectly influenced, as SCD1 is part of lipid synthesis. 2-Hydroxyoleic acid's impact on SCD1 can modulate ChREBP function, potentially affecting lipid metabolism and ChREBP-mediated gene expression. | ||||||
A-769662 | 844499-71-4 | sc-203790 sc-203790A sc-203790B sc-203790C sc-203790D | 10 mg 50 mg 100 mg 500 mg 1 g | $184.00 $741.00 $1076.00 $3417.00 $5304.00 | 23 | |
A-769662, an AMPK activator, modulates AMPK signaling. ChREBP, responsive to AMPK activation, can be indirectly affected, as AMPK inhibits ChREBP activity. A-769662's impact on AMPK signaling can modulate ChREBP function, potentially influencing glucose-responsive gene expression and lipid synthesis. | ||||||